Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,346.00
Bid: 12,376.00
Ask: 12,380.00
Change: 156.00 (1.28%)
Spread: 4.00 (0.032%)
Open: 12,304.00
High: 12,380.00
Low: 12,088.00
Prev. Close: 12,346.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: UK FCA charges NatWest with money-laundering failures

Tue, 16th Mar 2021 08:20

(Alliance News) - The City watchdog has launched criminal proceedings against taxpayer-backed lender NatWest Group for alleged failures under money laundering rules, PA reported Tuesday.

The Financial Conduct Authority alleges that "increasingly large cash deposits" were made into a NatWest customer's account, with around GBP365 million paid in – of which some GBP264 million was in cash.

It claims that NatWest's systems and controls failed to properly monitor and scrutinise this activity, which took place between November 11 2011 and October 19 2016.

NatWest is due to appear at Westminster Magistrates' Court on April 14.

It marks the first time the FCA has launched criminal prosecution under the money laundering regulations and the first time the rules have been used to prosecute a bank.

The FCA said the money laundering rules require firms to "determine, conduct and demonstrate risk sensitive due diligence and ongoing monitoring of its relationships with its customers for the purposes of preventing money laundering".

No individuals are being charged as part of the proceedings.

NatWest shares were down 0.8% early Tuesday.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: up 0.5% at 6,784.44

----------

Hang Seng: up 0.7% at 29,020.58

Nikkei 225: closed up 0.5% at 29,921.09

DJIA: closed up 174.82 points, 0.5%, at 32,953.46

S&P 500: closed up 0.7% at 3,968.94

Nasdaq Composite: closed up 1.1% at 13,459.71

----------

EUR: down at USD1.1922 (USD1.1931)

GBP: down at USD1.3832 (USD1.3885)

USD: up at JPY109.21 (JPY109.08)

Gold: down at USD1,728.85 per ounce (USD1,730.28)

Oil (Brent): down at USD68.23 a barrel (USD68.70)

(changes since previous London equities close)

----------

ECONOMICS AND GENERAL

----------

Tuesday's Key Economic Events still to come

US Federal Open Market Committee meeting starts

1100 CET Germany ZEW Indicator

0830 EDT US import & export price indexes

0830 EDT US retail sales

0855 EDT US Johnson Redbook retail sales index

0915 EDT US industrial production

1000 EDT US NAHB housing market index

1630 EDT US API Weekly statistical bulletin

----------

US and Japanese foreign and defence ministers warned on China, saying they had renewed a commitment to opposing "coercion and destabilising behaviour," during talks in Tokyo. "The US and Japan acknowledged that China's behaviour, where inconsistent with the existing international order, presents political, economic, military and technological challenges," they said in a joint statement on Tuesday. "The ministers committed to opposing coercion and destabilising behaviour towards others in the region," they added.

----------

BROKER RATING CHANGES

----------

JEFFERIES RAISES ASTRAZENECA TO 'BUY' (HOLD) - PRICE TARGET 8850 (8250) PENCE

----------

CREDIT SUISSE RAISES NATWEST TO 'OUTPERFORM' ('NEUTRAL') - TARGET 230 (170) P

----------

CREDIT SUISSE RAISES HSBC TO 'NEUTRAL' (UNDERPERFORM) - PRICE TARGET 440 (400) PENCE

CREDIT SUISSE RAISES BARCLAYS TO 'OUTPERFORM' (NEUTRAL) - PRICE TARGET 210 (155) PENCE

----------

BERENBERG INITIATES B&M EUROPEAN VALUE RETAIL WITH 'BUY' - TARGET 600 PENCE

----------

COMPANIES - FTSE 100

----------

AstraZeneca said it has modified an existing agreement with the US government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody combination which is in late-stage development for the prevention and treatment of Covid-19. The Anglo-Swedish drugmaker said the new US government deal builds on earlier deals for a total of 200,000 doses with the US Department of Health & Human Service and Department of Defense. The value of the extended agreement is USD205 million and is contingent on AZD7442 receiving and Emergency Use Authorisation from the US Food & Drug Administration. AstraZeneca said the total value of current agreements with the US government for the development and supply of AZD7442 in 2021 is about USD726 million. The extended agreement is not anticipated to effect the company's financial guidance for 2021.

----------

AstraZeneca also said it has completed the sale of its 27% stake in Viela Bio Inc to Horizon Therapeutics. It will receive USD775 million in cash proceeds and profit from the Viela stake sale, but this also isn't expected to affect its guidance for 2021.

----------

Chilean copper miner Antofagasta hiked its dividend as it reported positive annual results and a strengthened balance sheet. For 2020, revenue was up 3.3% to USD5.13 billion from USD4.94 billion in 2019. Pretax profit was USD1.41 billion, up 4.4% from USD1.35 billion. Earnings before interest, tax, depreciation and amortisation rose 12% to USD2.74 billion in 2020 from USD2.44 billion the year prior. The miner declared a final dividend of 48.5 cents per share, bringing the total dividend for the year to 54.7 cents per share, up from 17.8 cents in 2019. Chief Executive Ivan Arriagada said: "The year has been challenging, but we have successfully kept our people safe and healthy, achieved our production and exceeded our cost targets, and increased Ebitda by 12.3% to USD2.7 billion, yielding a 53% Ebitda margin...Our resilient operations performed well with high levels of throughput and our Cost & Competitiveness Programme delivered benefits of USD197 million, nearly double the targeted amount. Our balance sheet strengthened even further." Antofagasta said it had USD82 million in net debt at the end of 2020, for a net debt to Ebitda ratio of just 0.03 times.

----------

Plumbing and heating products supplier Ferguson said it delivered good top-line growth in the first half of its financial year and despite "challenging personal and professional" circumstances. For the half year ended January 31, revenue was up 4.2% to USD10.31 billion from USD9.89 billion at the same time the year before, and pretax profit rose 18% to USD739 million from USD628 million. Ferguson declared an interim dividend of 72.9 US cents, having paid out nothing the year before and said that now the disposal of its UK side has completed, a special dividend of 180 cents per share will be paid in May. It also announced a new USD400 million share buy back scheme. Ferguson completed the GBP308 million sale of heating & plumbing distribution business Wolseley UK to US private equity firm Clayton, Dubilier & Rice at the start of February.

----------

COMPANIES - FTSE 250

----------

Stockbroker AJ Bell confirmed it has picked Helena Morrissey as its next chair. Morrissey will join the AJ Bell board as chair designate on July 1 and succeed Les Platts as chair at the next annual general meeting in January next year. Morrissey will step down as a non-executive director of wealth manager St James's Place on July 1 "to avoid any potential conflict of interest", St James's Place said. Morrissey was head of Personal Investing at Legal & General Investment Management and prior to that chief executive of Newton Investment Management.

----------

COMPANIES - GLOBAL

----------

Credit Suisse confirmed that it has made "a strong start" to 2021, achieving the highest level of pretax income in both January and February in a decade. The Swiss bank said its Investment Bank division is benefiting from a "particularly strong" performance in capital markets issuance activity and from a continued "good" performance across sales & trading. Investment Bank year-to-date revenue is up over 50% compared to the prior year, Credit Suisse noted. It also reported increased client activity year-on-year, which was boosting all of its three Wealth Management-related businesses, while net interest income was also stabilising and recurring commissions and fees continued to trend up. "Notwithstanding the continued Covid-19 pandemic, our credit loss experience remains benign, with signs of improvement in the global economy beginning to benefit allowance for credit losses under the current expected credit loss accounting methodology," said Chief Executive Thomas Gottstein. Turning to the suspension and liquidation of the supply chain finance funds - with net asset value of USD10 billion - managed by Credit Suisse Asset Management with assets originated and structured by Greensill Capital, Credit Suisse said its priority remains the recovery of funds for its investors.

----------

Tuesday's Shareholder Meetings

Blackrock Energy & Resources Income Trust PLC - AGM

Blue Prism Group PLC - AGM

Plus500 Ltd - EGM

Starvest PLC - AGM

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.